SEC Form 4 · accession 0001237899-17-000033
REGENERON PHARMACEUTICALS, INC. · REGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Leonard S Schleifer
Officer — President & CEO · Director
Period of report
Dec 12, 2017
Accepted (ET)
Dec 13, 2017 · 5:17 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000872589
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Dec 13, 2017 | M | 250,000 | $21.92 | A | 407,409 | D | |
| Common Stock | Dec 13, 2017 | F | 14,230 | $385.08 | D | 393,179 | D | |
| Common Stock | Dec 13, 2017 | F | 121,586 | $385.08 | D | 271,593 | D | |
| Common Stock | holding | — | — | — | 5,729 | I | By 401(k) Plan |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F2 | $21.92 | Dec 13, 2017 | M | 250,000 | D | — | Dec 17, 2017 | Common Stock | 250,000 | 0 | D |
| Non-Qualified Stock Option (right to buy)F2 | $378.98 | Dec 12, 2017 | A | 139,474 | A | — | Dec 12, 2027 | Common Stock | 139,474 | 139,474 | D |
Explanation of responses
- F1Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
- F2The stock option award vests in four equal annual installments, commencing one year after the date of grant.